Eicarg Finance
Eicarg
™
Home
User Login
User Registration
Terms & Conditions
Privacy Policy
Contact Info
About
Eicarg Finance
Only Business & Financial News
CRVS stock rises on hopes of drug similar to AbbVie's $21 Billion Imbruvica
Abbvie purchased Pharmacyclic's Imbruvica back in 2015 for $21 billion. Now some of the same developers of Imbruvica have shown similar results with a similar drug in T cell lymphomas. Smaller market, but still could yield $1 billion.
Yahoo-Zacks Img:Reuters
2023-05-16 12:15:30
Brain Quest All About America - 600+ reviews - 1100 Questions and Answers!
AD - Eicarg Recommended!
/cloudfront-us-east-2.images.arcpublishing.com/reuters/GJYQ7CTX2FMJXKUIACX3MKA4H4.jpg)